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 Abstract 
Fibromyalgia (FMS) is a syndrome characterized by chronic widespread 
pain (CWP), which has no known etiology, and coincides with other 
life-altering symptoms including fatigue, mood disturbances, non-
restorative sleep, and muscular stiffness. Despite the multiple 
medication classes that are typically used for the treatment of FMS, 
there are no known studies assessing the efficacy of polypharmacy on 
symptoms of pain in this patient population. While analgesic 
medications, including opioid or opioid-like medications, are 
commonly prescribed, the use of these medications for FMS has not 
been fully described, including the potential incidence of analgesic 
overuse. The primary purpose of this secondary analysis was to examine 
how many classes of pharmacologic agents were used in a sample of 
N=122 women diagnosed with FMS, the relationships between baseline 
pain levels and medication use, controlling for self-reported levels of 
fatigue and depression. Data was collected from two separate studies: 
(a) a cross-sectional study to examine the relationship among stress, 
symptoms and immune markers in women (N=50) with FM, and (b) an 
RCT to examine the effect of a 10-week guided imagery intervention on 
stress, self-efficacy, symptoms and immunity in women (N=72) with 
FM. In both studies participants were asked to provide lists of currently 
prescribed medications for treatment of their FMS-related symptoms 
and complaints. Study outcomes revealed that participants were 
prescribed 6 different classes of medications. These included opioids 
analgesics, non-opioid analgesics, antidepressants, anticonvulsants, 
muscle relaxants, and benzodiazepines. Baseline pain severity 
(p=0.0106) and pain interference (p=0.0002) were significantly 
associated with opioid use as compared to those individuals who did 
not report opioid use. Study findings are considered preliminary data 
for development of a larger study to examine efficacy of polypharmacy, 
with and without opioids, for this chronic pain patient population and 
the related potential risk of adverse effects and substance abuse. 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The primary goal of this research project was to examine the 
relationships between pain levels and medication use in women 
diagnosed with fibromyalgia. The project is a secondary analysis of 
previously collected data from two studies conducted by Victoria 
Menzies, PhD, RN. The data utilized for this project was self-
reported baseline pain level scores (Brief Pain Inventory [BPI], 
Cleeland, 1989) and self-reported medication usage from a sample 
(N=122) of women with FM. Through examination of this data, we 
were able to answer the following proposed research questions: (1) 
“How many different classes of analgesic agents were used for 
individuals with FM?” and (2) “Do baseline pain scores differ in 
those individuals prescribed opioid medications compared to those 
who do not report opioid use?” 
Results/Discussion 
Table 1. Drug Use by Broad Categories in a Sample of N=122 
Women with FM  
 
 
 
 
 
 
 
 
 
 
 
Table 2. Scale Scores by Opioid Use 
 
 
 
 
 
 
The BPI Scores Range from 0 (no pain) to 10 (worst pain) 
(Mild Pain 1 – 4; Moderate Pain 5 – 6; Severe Pain 7 – 10)  
 
Study findings demonstrated that those participants who were  
taking opioid medications reported higher levels of baseline 
pain scores than those who were not taking opioids. Baseline 
pain severity (p=0.0106) and pain interference (p=0.0002) scores 
were significantly associated with opioid use as compared to 
those individuals who did not report opioid use. 
 
Pharmacologic interventions are predicated on the current best 
understanding of FMS as a centralized pain condition (Clauw, 
2014). Central pain conditions are those in which persistent 
pain occurs as result of abnormal alterations of central 
ascending and descending pain pathways, the outcome of which 
is augmented central nervous system pain processing. That is, 
pain persists in the absence of anatomic anomalies and without 
there being any proof of nociceptive input from the peripheral 
nervous system (Üçeyler et al., 2013; Clauw & McCarberg, 
2012).  Just as there is lack of objective evidence for nociceptive 
signaling from the peripheral nervous system, medications 
commonly used to treat peripheral pain, such as opioids,  may 
be ineffective for symptom reduction in FMS.  
Conclusion 
Further examination of pain management strategies is warranted in 
this patient population, especially where potentially negative effects 
of polypharmacy are considered.  
 
Researchers have suggested that hyporeactivity of the hypothalamus-
pituitary-adrenal (HPA) axis, increased inflammatory processes, and/
or dysfunction of neurotransmitters in the brain (dopamine, 
serotonin, norepinephrine, glutamate, substance P) are likely 
associated with this centralized pain state in FMS Therefore, 
medication management appears to be most often approached 
within the context of neurotransmitters and their role in analgesic 
activity.  For example, pain relieving effects of anticonvulsants have 
been attributed to reduced release of several pain pathway 
neurotransmitters, particularly glutamate and substance P, both of 
which play a facilitory role in pain processing (Mease, Dundon, & 
Sarzi-Puttini, 2011; Üçeyler et al., 2013). Other neurotransmitters, 
considered to contribute to inhibition of pain processing, are 
norepinephrine, serotonin and gamma-aminobutyric acid (GABA) 
(Clauw, 2014; Clauw & McCarberg, 2012).  
 
Therefore it is recommended that future longitudinal studies  should 
include an examination of those medications which effect 
modulating and inhibitory neurotransmitters and examine them in 
relation to pain and other symptoms  of fibromyalgia.   
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Categories % (n) 
Opioids 30% (37) 
Non-Opioid Analgesics 50% (61) 
Antidepressants 58% (71) 
Anticonvulsants 31% (38) 
Muscle Relaxants 41% (50) 
Benzodiazepines 24% (29) 
Any Non-Opioid Pain Med Use 87% (106) 
Scale Total      
(n=122) 
Opioid Use No 
(n=85) 
Opioid Use Yes 
(n=37 
p-value 
BPI Severity 5.39 (2.01) 5.09 (1.97) 6.10 (1.95) 0.01061 
 
BPI 
Interference 
5.69 (2.54) 5.12 (2.44) 6.97 (2.29) 0.00021 
